Filter

Refine by Subjects

Refine by Access

Refine by Type

Refine by Date

—
  • Print
  • Save

Browse

You are looking at 251 - 300 of 932 items for :

  • Drug Information x
  • Refine by Access: All content x
Clear All
Restricted access

Carvedilol Suspension 0.1 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Carvedilol Suspension 1.67 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Carvedilol Suspension 5 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Cefazolin Sodium Ophthalmic Solution 33 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Celecoxib Suspension 10 mg/mL—Formulation 1

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Celecoxib Suspension 10 mg/mL—Formulation 2

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Chloroquine Phosphate Suspension 15 mg/mL—Formulation 1

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Chloroquine Phosphate Suspension 15 mg/mL—Formulation 2

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Chloroquine Phosphate Syrup 16.7 mg/mL*

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Chlorpromazine Hydrochloride Syrup 100 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Cholecalciferol Suspension 50,000 units/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Cidofovir Intravitreous Solution 0.2 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Cidofovir Intravitreous Solution 8.1 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Cinacalcet Suspension 5 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Ciprofloxacin Hydrochloride Suspension 50 mg/mL—Formulation 1

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Ciprofloxacin Hydrochloride Suspension 50 mg/mL—Formulation 2

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Clonazepam Suspension 0.1 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Clonazepam Suspension 0.2 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Clonidine Hydrochloride Suspension 0.01 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Clonidine Hydrochloride Syrup 0.02 mg/mL*

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Clonidine Hydrochloride Syrup 0.1 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Clopidogrel Bisulfate Suspension 5 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Codeine Phosphate Syrup 3 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Commercially Available Products (Use Only if Commercially Unavailable)

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover
Published (Print):
Jan 2022
Restricted access

Cyclophosphamide Suspension 10 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Cyclosporine Suspension 100 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Dantrolene Sodium Syrup 5 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Dapsone Suspension 2 mg/mL—Formulation 1

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Dapsone Suspension 2 mg/mL—Formulation 2

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Dapsone Syrup 2 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Dexamethasone Suspension 1 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Diazoxide Suspension 10 mg/mL—Formulation 1

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Diazoxide Suspension 10 mg/mL—Formulation 2

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Diclofenac Sodium Suspension 5 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Diltiazem Hydrochloride Suspension 12 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Diltiazem Suspension 12 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Dipyridamole Suspension 10 mg/mL—Formulation 1

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Dipyridamole Suspension 10 mg/mL—Formulation 2

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Disopyramide Syrup 1 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Disopyramide Syrup 10 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Dolasetron Mesylate Suspension 10 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Enalapril Maleate Suspension 0.1 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Enalapril Maleate Suspension 1 mg/mL—Formulation 1

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Enalapril Maleate Suspension 1 mg/mL—Formulation 2

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Enalapril Maleate Suspension 1 mg/mL—Formulation 3

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Erlotinib Suspension 10 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Eslicarbazepine Acetate Suspension 40 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Ethacrynic Acid Solution 1 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access

Etoposide Solution 10 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Chapter

Cover Extemporaneous Formulations

In  Extemporaneous Formulations

Published (Print):
Jan 2022
Restricted access
Cover Extemporaneous Formulations

Extemporaneous Formulations

for Pediatric, Geriatric, and Special Needs Patients

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Book

Published (Print):
Jan 2022